Group 1 - The construction of the commercial health insurance drug directory has made new progress, with the China Insurance Industry Association soliciting opinions on the draft of the commercial health insurance drug directory-A series [1] - The goal is to establish a comprehensive and multi-tiered commercial health insurance drug directory system, expanding coverage to all drugs approved by domestic and foreign drug regulatory agencies [1] - The directory will be designed based on different customer segments, including A series for affordable insurance products, B series for million medical insurance products, and C series for mid-range medical insurance products [1] Group 2 - The working group has compiled a draft of the commercial health insurance drug directory-A series, which includes 19 indications based on a survey of customized commercial medical insurance products across 29 provinces, autonomous regions, and municipalities [2] - The draft focuses on 2,619 specific drugs, sorted by frequency, and aims to address the differences in premium scale, coverage, product pricing, and sales duration among various regional products [2] - The working group encourages health insurance companies to provide feedback on the directory structure, drug range, implementation suggestions, and how companies can reference the directory to enhance market alignment and product design [2]